Longeveron to Participate in Three Longevity/Aging Investment ConferencesGlobeNewsWire · Sep 30, 2026
Longeveron explores strategic options after therapy fails mid-stage trial for infant heart conditionReuters · Sep 16, 2026
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)GlobeNewsWire · Sep 16, 2026
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 3, 2026
Longeveron Announces 1-for-10 Reverse Stock SplitGlobeNewsWire · Aug 24, 2026
Longeveron Appoints Nirav Jhaveri as Chief Financial OfficerGlobeNewsWire · Aug 19, 2026Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$1.75 | -$1.90 | Miss |
| May 13, 2026 | -$1.80 | -$0.19 | Beat |
| Mar 17, 2026 | -$4.20 | -$2.30 | Beat |
| Nov 4, 2025 | -$2.60 | -$0.39 | Beat |
| Aug 13, 2025 | -$0.35 | -$0.33 | Beat |
| May 8, 2025 | -$3.40 | -$0.34 | Beat |